Is Cordlife A Potential High Growth Company?
Cordlife Group Limited (P8A.SI)
Target Price: $1.03
Last Closed Price: $1.20
Source: Yahoo Finance (Sep 9,2016)
Summary
- Change of Chief Executive Officer
- Financials giving off mixed signals.
- Positive Market Trends with high grow potential, increasing birth rates and regional business expansions
- Abundance of possibilities for revenue growth
1. What Business Cordlife Group (P8A.SI) Is In
A consumer healthcare company founded in Singapore which provides consumer healthcare products and services to the general public.
Products & Services:
• Cord Blood Banking
• Cord Lining Banking
• Metascreen (Detection of Metabolic Disorders)
• iGene – Non Invasive Prenatal Test
• Eyescreen (Detection of Vision Problems)
2. What Happened to Cordlife …show more content…
However, competition level differs in different regions. In more regulated markets such as China, a private blood banker operates as a monopoly, while in less regulated markets, competition can be observed growing.
Singapore- Stemcord is the only competitor to Cordlife in private cord blood banking. However, Cordlife is able to stay ahead of Stemcord due to the adaptation of the latest technology such as SEPAX® 2. Cordlife enjoys approximately 62% of the market share in Singapore.
Hong Kong- There are two other major competitors of Cordlife in Hong Kong, which are Cryolife and Healthbaby. However, Cordlife is still able to distinguish itself from its’ competition and maintains 27% of the market share.
China- Cordlife is able to establish a strong foothold in China through collaboration with CCBC, which operates 4 out of 7 licensed cord blood banks in China. CCBC is now responsible for 62% market share in China.
India, the Philippines and Indonesia- Cordlife has the largest market share of private blood banking in the Philippines and Indonesia and the 3rd largest market share in India.
5.
Cordlife Group Limited (P8A.SI)
Target Price: $1.03
Last Closed Price: $1.20
Source: Yahoo Finance (Sep 9,2016)
Summary
- Change of Chief Executive Officer
- Financials giving off mixed signals.
- Positive Market Trends with high grow potential, increasing birth rates and regional business expansions
- Abundance of possibilities for revenue growth
1. What Business Cordlife Group (P8A.SI) Is In
A consumer healthcare company founded in Singapore which provides consumer healthcare products and services to the general public.
Products & Services:
• Cord Blood Banking
• Cord Lining Banking
• Metascreen (Detection of Metabolic Disorders)
• iGene – Non Invasive Prenatal Test
• Eyescreen (Detection of Vision Problems)
2. What Happened to Cordlife …show more content…
However, competition level differs in different regions. In more regulated markets such as China, a private blood banker operates as a monopoly, while in less regulated markets, competition can be observed growing.
Singapore- Stemcord is the only competitor to Cordlife in private cord blood banking. However, Cordlife is able to stay ahead of Stemcord due to the adaptation of the latest technology such as SEPAX® 2. Cordlife enjoys approximately 62% of the market share in Singapore.
Hong Kong- There are two other major competitors of Cordlife in Hong Kong, which are Cryolife and Healthbaby. However, Cordlife is still able to distinguish itself from its’ competition and maintains 27% of the market share.
China- Cordlife is able to establish a strong foothold in China through collaboration with CCBC, which operates 4 out of 7 licensed cord blood banks in China. CCBC is now responsible for 62% market share in China.
India, the Philippines and Indonesia- Cordlife has the largest market share of private blood banking in the Philippines and Indonesia and the 3rd largest market share in India.
5.